Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eptacog alfa inhalation - Savara Pharmaceuticals

Next Previous
Search
Drug Profile

Eptacog alfa inhalation - Savara Pharmaceuticals

Alternative Names: Recombinant FVIIa inhalation - Serendex; Recombinant human factor VIIa inhalation - Serendex; rhFVIIa inhalation - Serendex

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CMC Biologics
  • Developer AGC Biologics; Savara Pharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor IX stimulants; Factor X stimulants; Haemostasis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haemorrhage

Most Recent Events

  • 18 Jul 2016 Serendex Pharmaceuticals has been acquired and merged into Savara Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for research development in Haemorrhage in Denmark (Inhalation, Inhalant)
  • 21 Jun 2016 Savara Pharmaceuticals acquires eptacog alfa inhalation from Serendex Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top